AU736339B2 - Liquid gonadotropin containing formulations - Google Patents

Liquid gonadotropin containing formulations Download PDF

Info

Publication number
AU736339B2
AU736339B2 AU52059/98A AU5205998A AU736339B2 AU 736339 B2 AU736339 B2 AU 736339B2 AU 52059/98 A AU52059/98 A AU 52059/98A AU 5205998 A AU5205998 A AU 5205998A AU 736339 B2 AU736339 B2 AU 736339B2
Authority
AU
Australia
Prior art keywords
gonadotropin
formulation
liquid
containing formulation
liquid gonadotropin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU52059/98A
Other languages
English (en)
Other versions
AU5205998A (en
Inventor
Petrus Johannes Maria Oetelaar
Arnold Titus Philip Skrabanja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU5205998A publication Critical patent/AU5205998A/en
Application granted granted Critical
Publication of AU736339B2 publication Critical patent/AU736339B2/en
Assigned to N.V. ORGANON reassignment N.V. ORGANON Alteration of Name(s) in Register under S187 Assignors: AKZO NOBEL N.V.
Assigned to MSD OSS B.V. reassignment MSD OSS B.V. Request to Amend Deed and Register Assignors: N.V. ORGANON
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Request to Amend Deed and Register Assignors: MSD OSS B.V.
Assigned to N.V. ORGANON reassignment N.V. ORGANON Request for Assignment Assignors: MERCK SHARP & DOHME B.V.
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52059/98A 1997-01-15 1998-01-14 Liquid gonadotropin containing formulations Expired AU736339B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15
EP97200099 1997-01-15

Publications (2)

Publication Number Publication Date
AU5205998A AU5205998A (en) 1998-07-23
AU736339B2 true AU736339B2 (en) 2001-07-26

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52059/98A Expired AU736339B2 (en) 1997-01-15 1998-01-14 Liquid gonadotropin containing formulations

Country Status (29)

Country Link
US (1) US5929028A (enExample)
EP (2) EP0853945B1 (enExample)
JP (1) JP4353549B2 (enExample)
KR (1) KR100498531B1 (enExample)
CN (1) CN1165341C (enExample)
AR (1) AR011410A1 (enExample)
AT (1) ATE237348T1 (enExample)
AU (1) AU736339B2 (enExample)
BR (1) BR9800323B1 (enExample)
CA (1) CA2226803A1 (enExample)
CZ (1) CZ297419B6 (enExample)
DE (2) DE122010000011I1 (enExample)
DK (1) DK0853945T3 (enExample)
ES (1) ES2196474T3 (enExample)
FR (1) FR10C0024I2 (enExample)
HU (1) HU227154B1 (enExample)
ID (1) ID19499A (enExample)
IL (1) IL122732A0 (enExample)
LU (1) LU91655I2 (enExample)
MX (1) MX9800438A (enExample)
NO (3) NO322509B1 (enExample)
NZ (1) NZ329572A (enExample)
PL (1) PL190103B1 (enExample)
PT (1) PT853945E (enExample)
RU (1) RU2203086C2 (enExample)
SA (1) SA98181124B1 (enExample)
TR (1) TR199800062A2 (enExample)
TW (1) TW518235B (enExample)
ZA (1) ZA9883B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
WO2000004913A1 (en) * 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
BR0013162A (pt) * 1999-07-12 2002-05-28 Grandis Biotech Gmbh Formulações de hormÈnio de crescimento
PL207728B1 (pl) * 2000-02-22 2011-01-31 Serono Lab Sposób oczyszczania LH z próbki, zastosowanie rekombinowanego hLH oraz kompozycja farmaceutyczna
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (en) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Image forming method
NZ542549A (en) 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
UA91960C2 (ru) * 2003-04-02 2010-09-27 Эйрес Трейдинг С.А. Жидкие фармацевтические композиции fsh и lh
ATE492292T2 (de) * 2003-04-02 2011-01-15 Ares Trading Sa Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2526099C (en) * 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007056851A1 (en) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions and methods for enhancing ovulation inducing agents
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
JPWO2008038817A1 (ja) * 2006-09-25 2010-01-28 国立大学法人東京農工大学 超音波操作装置および微細管内検査システム
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
RS52976B (sr) 2007-06-28 2014-02-28 Biogenerix Ag Ćelijski klon koji proizvodi fsh
RS52566B (sr) * 2007-11-01 2013-04-30 Merck Serono S.A. Tečne formulacije lh
ME01337B (me) * 2008-02-08 2013-12-20 Biogenerix Ag Tečni preparat fsh
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
MX2011004453A (es) 2008-11-04 2011-08-12 Aska Pharm Co Ltd Composicion acuosa que contiene hormona foliculo estimulante.
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012127501A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX2014012625A (es) 2012-04-19 2015-05-15 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
US20150290292A1 (en) 2012-10-18 2015-10-15 Neuralight Hd, Llc Treatment of Depression and PTSD
BR112015011583B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
KR20150126042A (ko) 2013-03-12 2015-11-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 액체 수성 조성물
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN105658201A (zh) 2013-11-12 2016-06-08 卡迪拉保健有限公司 促性腺激素的制剂
HRP20211477T8 (hr) * 2014-10-21 2022-03-04 Hexima Limited Postupak liječenja gljivičnih infekcija
SG11201704706RA (en) 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
WO2018011799A1 (en) 2016-07-11 2018-01-18 Opko Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN117783545A (zh) * 2023-12-28 2024-03-29 深圳市新产业生物医学工程股份有限公司 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448146A1 (en) * 1990-03-20 1991-09-25 Akzo Nobel N.V. Stabilized gonadotropin containing preparations
WO1993011788A1 (en) * 1991-12-18 1993-06-24 Applied Research Systems Ars Holding N.V. Gonadotropin containing pharmaceutical compositions with sucrose stabilizer
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
EP0461200B1 (en) * 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
CA2573307C (en) * 1992-04-30 2011-01-04 Millennium Pharmaceuticals, Inc. Use of platelet aggregation inhibitors
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448146A1 (en) * 1990-03-20 1991-09-25 Akzo Nobel N.V. Stabilized gonadotropin containing preparations
WO1993011788A1 (en) * 1991-12-18 1993-06-24 Applied Research Systems Ars Holding N.V. Gonadotropin containing pharmaceutical compositions with sucrose stabilizer
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations

Also Published As

Publication number Publication date
US5929028A (en) 1999-07-27
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
SA98181124B1 (ar) 2006-07-10
DK0853945T3 (da) 2003-08-04
ZA9883B (en) 1998-07-08
NO322509B1 (no) 2006-10-16
KR19980070493A (ko) 1998-10-26
RU2203086C2 (ru) 2003-04-27
CN1165341C (zh) 2004-09-08
AU5205998A (en) 1998-07-23
ID19499A (id) 1998-07-16
NO2010013I2 (no) 2015-05-18
FR10C0024I1 (enExample) 2010-05-21
HU227154B1 (en) 2010-08-30
IL122732A0 (en) 1998-08-16
AR011410A1 (es) 2000-08-16
EP1285665A1 (en) 2003-02-26
HUP9800056A2 (hu) 1998-08-28
HK1010150A1 (en) 1999-06-17
HU9800056D0 (en) 1998-03-02
NO2021001I1 (no) 2021-01-12
NO2010013I1 (no) 2010-06-07
NO980177L (no) 1998-07-16
DE69813322D1 (de) 2003-05-22
JPH10203997A (ja) 1998-08-04
LU91655I2 (fr) 2010-04-26
NO980177D0 (no) 1998-01-14
PL324279A1 (en) 1998-07-20
PT853945E (pt) 2003-08-29
ES2196474T3 (es) 2003-12-16
BR9800323A (pt) 1999-06-29
EP0853945B1 (en) 2003-04-16
NZ329572A (en) 1999-05-28
MX9800438A (es) 1998-11-30
DE69813322T2 (de) 2004-02-19
DE122010000011I1 (de) 2010-07-08
CZ297419B6 (cs) 2006-12-13
KR100498531B1 (ko) 2005-09-30
EP0853945A1 (en) 1998-07-22
CN1191139A (zh) 1998-08-26
TR199800062A2 (xx) 1998-08-21
TW518235B (en) 2003-01-21
JP4353549B2 (ja) 2009-10-28
CA2226803A1 (en) 1998-07-15
FR10C0024I2 (fr) 2011-04-01
CZ13598A3 (cs) 1998-08-12
PL190103B1 (pl) 2005-10-31
HUP9800056A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
AU736339B2 (en) Liquid gonadotropin containing formulations
EP0448146B1 (en) Stabilized gonadotropin containing preparations
US8664369B2 (en) LH liquid formulations
AU2009211331B2 (en) Liquid formulation of FSH
RU2553375C2 (ru) Жидкий состав фолликулостимулирующего гормона
US5384132A (en) Stabilized gonadotropin containing preparations
AU2004248931B2 (en) Freeze-dried FSH / LH formulations
US5270057A (en) Stabilized gonadotropin containing preparations
HK1010150B (en) Liquid gonadotropin containing formulations
HK1002494B (en) Stabilized gonadotropin containing preparations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: N.V. ORGANON

Free format text: FORMER OWNER(S): MERCK SHARP & DOHME B.V.